# 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Pneumococcal Vaccine-Naïve Adults 60 Years of Age and Older in Japan, Korea, and Taiwan

> **NCT04875533** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 1425 (actual)

## Conditions studied

- Pneumococcal Disease

## Interventions

- **BIOLOGICAL:** 20vPnC
- **OTHER:** Saline
- **BIOLOGICAL:** 13vPnC
- **BIOLOGICAL:** PPSV23

## Key facts

- **NCT ID:** NCT04875533
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-14
- **Primary completion:** 2022-05-13
- **Final completion:** 2022-05-13
- **Target enrollment:** 1425 (ACTUAL)
- **Last updated:** 2024-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04875533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04875533, "20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Pneumococcal Vaccine-Naïve Adults 60 Years of Age and Older in Japan, Korea, and Taiwan". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04875533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*